February 2018

New Contraindications

Combined oral contraceptives (COCs) including Brevinor, Brevinor-1, Norimin, Norimin-1 (norethisterone/ethinylestradiol), Loette, Monofeme, Nordette, Trifeme, Triphasil (levonorgestrel/ethinylestradiol) and Minulet (gestodene/ethinylestradiol) are now contraindicated with concomitant use of certain antiviral hepatitis C virus (HCV) medicinal products such as ombitasvir, paritaprevir, ritonavir and dasabuvir ┬▒ ribavirin due to increased risk of ALT elevations higher than 5 times the upper limit of normal. COC users must switch to an alternative method of contraception (e.g. progestogen only contraception or nonhormonal methods) prior to starting therapy with antiviral HCV medicinal products. COCs can be restarted 2 weeks following completion of HCV antiviral treatment.

Cervidil (dinoprostone) should not be used or left in place when other labour inducing agents are being given or if they are to be given intravenously within 30 minutes, or when strong prolonged uterine contractions would be inappropriate such as previous major uterine surgery (e.g. myomectomy).

Noriday 28 (norethisterone) is now contraindicated with hepatic adenomas or carcinomas.

Prednefrin Forte (prednisolone acetate/phenylephrine hydrochloride) is now contraindicated with mycobacterial infection of the eye, or narrow angle glaucoma.

This list is a summary of only some of the changes that have occurred over the last month. Before prescribing, always refer to the full product information.

Copyright © MIMS Australia┬áPty Ltd. All rights reserved.

MIMS Australia
Level 2, 1 Chandos Street
St Leonards NSW 2065
Phone: 1800 800 629